Salud financiera de hoja de balance de Noxopharm

Salud financiera controles de criterios 6/6

Noxopharm tiene un patrimonio de los accionistas total de A$6.6M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$7.2M y A$580.8K respectivamente.

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$2.32m
Patrimonio	AU$5.50m
Total pasivo	AU$1.29m
Activos totales	AU$6.78m

Actualizaciones recientes sobre salud financiera

Recent updates

Here's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn Situation

Aug 24

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Jan 04

We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Jul 22

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Feb 27

We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Nov 10

Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Jun 04

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 17

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

Sep 04

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$6.4M) de NOX superan a sus pasivos a corto plazo (A$499.5K).

Pasivo a largo plazo: Los activos a corto plazo de NOX (A$6.4M) superan a sus pasivos a largo plazo (A$81.3K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: NOX está libre de deudas.

Reducción de la deuda: NOX actualmente no tiene deuda, sin embargo, no podemos comparar con hace 5 años ya que no disponemos de datos de ese periodo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: NOX tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: NOX dispone de suficiente cash runway para 1.9 años si el flujo de caja libre sigue creciendo a tasas históricas de 7.5% cada año.

Salud financiera de hoja de balance de Noxopharm

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Here's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn Situation

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Recent updates

Here's Why We're Watching Noxopharm's (ASX:NOX) Cash Burn Situation

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Share price stability

New major risk - Financial position

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

New minor risk - Financial data availability

Non-Executive Chairman recently bought AU$50k worth of stock

Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Noxopharm Limited Announces Award of Federal Innovation Connections Grant

Noxopharm Limited Announces CEP-2 Safety Milestone Shows Veyonda Progress

No independent directors

Insider recently sold AU$278k worth of stock

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Full year 2022 earnings released: AU$0.064 loss per share (vs AU$0.035 loss in FY 2021)

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Noxopharm Limited Reviews the Safety Data from the First Cohort of Patients in the Trial

Noxopharm Limited Announces DARRT-2 Trial Safety Milestone and European Site Activated

We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Noxopharm Limited Announces Mayo Clinic and Washington University Join Its Sarcoma Trial

Veyonda Abstract Published at ASCO Annual Meeting 2022

No independent directors

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Noxopharm Limited Announces Phase 1 CEP-2 Sarcoma Trial is Underway with a First Patient Enrolled and Dosed At City of Hope in Los Angeles, California

Noxopharm Limited Announces First Patient Dosed in CEP-2 Sarcoma Trial at the US City of Hope Cancer Center

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Noxopharm Limited Announces Veyonda Achieves Important U.S. Patent Claims

Noxopharm Announces Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Full year 2021 earnings released: AU$0.035 loss per share (vs AU$0.002 loss in FY 2020)

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Noxopharm Limited Releases Preliminary Top Line Data of Its NOXCOVID Phase 1 Clinical Trial

Noxopharm Limited's DARRT-2 Study Receives IND Approval from FDA

Noxopharm Limited Updates the Market on Progress with its DARRT-2 Trial

Noxopharm Limited Announces the Release of Clinical Data Relating to the Experimental Radioligand

Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Noxopharm Limited Announces New Independent Trial Data Supports Potential of Veyonda as Major New Anti-Cancer Drug

Noxopharm Limited’s Veyonda to Begin First-Line Sarcoma Treatment Testing

Oxopharm Limited Announces That Its Cep-2 Study Will Open Shortly

Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm

Noxopharm IONIC Immuno-Oncology Trial Commences

Noxopharm Limited Announces Veyonda Approved to Move into Second and Final Stage of the NOXCOVID-1 Clinical Trial on the Advice of the Clinicians Treating the NOXCOVID-1 Patients

Founder exercised options to buy AU$5.5m worth of stock.

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Noxopharm Limited Provides More Detailed Summary of Data from the Lupin Study That Formally Presented to the American Society of Clinical Oncology Genitourinary Cancers Symposium

Noxopharm Limited Reports the Publication in Abstract Form of the Latest Survival Data from the LuPIN Study

New 90-day high: AU$0.69

Noxopharm Limited Announces the Latest Formal Review by the NOXCOVID-1 Safety Steering Committee Cleared it to Advance to the Fifth and Final Dosage Cohort

Noxopharm Limited Provides Update on Its Ongoing New Immuno-Oncology Drug

Noxopharm Limited Announces Independent Discovery Validates Darrt Cancer Therapy

New 90-day high: AU$0.54

Noxopharm Limited Announce Partnership with Hudson Institute of Medical Research and Australian National University for the Formation of the New Australian Drug Development Company

New 90-day high: AU$0.44

Noxopharm Limited Announces the Final Patient Has Completes Treatment in the Lupin Study

Noxopharm Announces First COVID-19 Patient Treated in Veyonda Study

Noxopharm Limited Announces the Enrolment and Treatment of the First Patient into the Phase 1 NOXCOVID-1

New 90-day high: AU$0.39

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera